Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Huarte, E; Sarobe, P; Lasarte, JJ; Brem, G; Weiss, EH; Prieto, J; Borras-Cuesta, F
   Identification of HLA-B27-restricted cytotoxic T lymphocyte epitope from carcinoembryonic antigen
   INTERNATIONAL JOURNAL OF CANCER
   
   E. Huarte et al., "Identification of HLA-B27-restricted cytotoxic T lymphocyte epitope from carcinoembryonic antigen", INT J CANC, 97(1), 2002, pp. 58-63
2. Ferroni, P; Di Filippo, F; Martini, F; Spila, A; D'Alessandro, R; Cavaliere, F; Anza, M; Garinei, R; Aloe, S; Carone, MD; Gazzaniga, PP; Guadagni, F
   Effects of isolated limb perfusion with tumor necrosis factor-alpha on circulating levels of proinflammatory cytokines
   JOURNAL OF IMMUNOTHERAPY
   
   P. Ferroni et al., "Effects of isolated limb perfusion with tumor necrosis factor-alpha on circulating levels of proinflammatory cytokines", J IMMUNOTH, 24(4), 2001, pp. 354-362
3. Zeng, G
   MHC class II-restricted tumor antigens recognized by CD4(+) T cells: New strategies for cancer vaccine design
   JOURNAL OF IMMUNOTHERAPY
   
   G. Zeng, "MHC class II-restricted tumor antigens recognized by CD4(+) T cells: New strategies for cancer vaccine design", J IMMUNOTH, 24(3), 2001, pp. 195-204
4. Treon, SP; Mitsiades, C; Mitsiades, N; Young, G; Doss, D; Schlossman, R; Anderson, KC
   Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies
   JOURNAL OF IMMUNOTHERAPY
   
   S.P. Treon et al., "Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies", J IMMUNOTH, 24(3), 2001, pp. 263-271
5. Maliner-Stratton, MS; Klein, RD; Udayakumar, TS; Nagle, RB; Bowden, GT
   Interleukin-1 beta-induced promatrilysin expression is mediated by NF kappa B-regulated synthesis of interleukin-6 in the prostate carcinoma cell line, LNCaP
   NEOPLASIA
   
   M.S. Maliner-Stratton et al., "Interleukin-1 beta-induced promatrilysin expression is mediated by NF kappa B-regulated synthesis of interleukin-6 in the prostate carcinoma cell line, LNCaP", NEOPLASIA, 3(6), 2001, pp. 509-520
6. Kim, SJ; Uehara, H; Karashima, T; Mccarty, M; Shih, N; Fidler, IJ
   Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice
   NEOPLASIA
   
   S.J. Kim et al., "Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice", NEOPLASIA, 3(1), 2001, pp. 33-42
7. Wang, RF
   The role of MHC class II-restricted tumor antigens and CD4(+) T cells in antitumor immunity
   TRENDS IN IMMUNOLOGY
   
   R.F. Wang, "The role of MHC class II-restricted tumor antigens and CD4(+) T cells in antitumor immunity", TRENDS IMMU, 22(5), 2001, pp. 269-276
8. Bodey, B
   Genetically engineered antibodies for direct antineoplastic treatment and systematic delivery of various therapeutic agents to cancer cells
   EXPERT OPINION ON BIOLOGICAL THERAPY
   
   B. Bodey, "Genetically engineered antibodies for direct antineoplastic treatment and systematic delivery of various therapeutic agents to cancer cells", EXPERT OP B, 1(4), 2001, pp. 603-617
9. Scanlan, MJ; Jager, D
   Challenges to the development of antigen-specific breast cancer vaccines
   BREAST CANCER RESEARCH
   
   M.J. Scanlan e D. Jager, "Challenges to the development of antigen-specific breast cancer vaccines", BREAST CA R, 3(2), 2001, pp. 95-98
10. Komba, S; Yamaguchi, M; Ishida, H; Kiso, M
    6-O-sulfo de-N-acetylsialyl Lewis X as a novel high-affinity ligand for human L-selectin: Total synthesis and structural characterization
    BIOLOGICAL CHEMISTRY
    
    S. Komba et al., "6-O-sulfo de-N-acetylsialyl Lewis X as a novel high-affinity ligand for human L-selectin: Total synthesis and structural characterization", BIOL CHEM, 382(2), 2001, pp. 233-240
11. Beck, A; Bussat, MC; Klinguer-Hamour, C; Goetsch, L; Aubry, JP; Champion, T; Julien, E; Haeuw, JF; Bonnefoy, JY; Corvaia, N
    Stability and CTL activity of N-terminal glutamic acid containing peptides
    JOURNAL OF PEPTIDE RESEARCH
    
    A. Beck et al., "Stability and CTL activity of N-terminal glutamic acid containing peptides", J PEPT RES, 57(6), 2001, pp. 528-538
12. Albertini, MR; King, DM; Newton, MA; Vacek, PM
    In vivo mutant frequency of thioguanine-resistant T-cells in the peripheral blood and lymph nodes of melanoma patients
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
    
    M.R. Albertini et al., "In vivo mutant frequency of thioguanine-resistant T-cells in the peripheral blood and lymph nodes of melanoma patients", MUT RES-F M, 476(1-2), 2001, pp. 83-97
13. Frank, S; Ebert, AD
    License to kill tumors: How much hope is justified for trail?
    CURRENT PHARMACEUTICAL DESIGN
    
    S. Frank e A.D. Ebert, "License to kill tumors: How much hope is justified for trail?", CUR PHARM D, 7(16), 2001, pp. 1689-1701
14. Lalla, RV; Goralnick, SJ; Tanzer, ML; Kreutzer, DL
    Fibrin induces IL-8 expression from human oral squamous cell carcinoma cells
    ORAL ONCOLOGY
    
    R.V. Lalla et al., "Fibrin induces IL-8 expression from human oral squamous cell carcinoma cells", ORAL ONCOL, 37(3), 2001, pp. 234-242
15. Neamati, N
    A small-molecule antagonist of virion assembly
    EXPERT OPINION ON INVESTIGATIONAL DRUGS
    
    N. Neamati, "A small-molecule antagonist of virion assembly", EXPERT OP I, 10(9), 2001, pp. 1767-1771
16. Mitsiades, N; Mitsiades, CS; Poulaki, V; Anderson, KC; Treon, SP
    Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma andother neoplasias
    EXPERT OPINION ON INVESTIGATIONAL DRUGS
    
    N. Mitsiades et al., "Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma andother neoplasias", EXPERT OP I, 10(8), 2001, pp. 1521-1530
17. Correale, P; Sabatino, M; Cusi, MG; Micheli, L; Nencini, C; Pozzessere, D; Petrioli, R; Aquino, A; De Vecchis, L; Turriziani, M; Prete, SP; Sanguedolce, R; Rausa, L; Giorgi, G; Francini, G
    In vitro generation of cytotoxic T lymphocytes against HLA-A2.1-restrictedpeptides derived from human thymidylate synthase
    JOURNAL OF CHEMOTHERAPY
    
    P. Correale et al., "In vitro generation of cytotoxic T lymphocytes against HLA-A2.1-restrictedpeptides derived from human thymidylate synthase", J CHEMOTHER, 13(5), 2001, pp. 519-526
18. Schneider, GP; Salcedo, R; Welniak, LA; Howard, OMZ; Murphy, WJ
    The diverse role of chemokines in tumor progression: Prospects for intervention (Review)
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
    
    G.P. Schneider et al., "The diverse role of chemokines in tumor progression: Prospects for intervention (Review)", INT J MOL M, 8(3), 2001, pp. 235-244
19. Hernandez, A; Wang, QD; Schwartz, SA; Evers, BM
    Sensitization of human colon cancer cells to TRAIL-mediated apoptosis
    JOURNAL OF GASTROINTESTINAL SURGERY
    
    A. Hernandez et al., "Sensitization of human colon cancer cells to TRAIL-mediated apoptosis", J GASTRO S, 5(1), 2001, pp. 56-65
20. Sanderson, RD
    Heparan sulfate proteoglycans in invasion and metastasis
    SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
    
    R.D. Sanderson, "Heparan sulfate proteoglycans in invasion and metastasis", SEM CELL D, 12(2), 2001, pp. 89-98
21. Shi, Q; Xiong, QG; Le, XD; Xie, KP
    Regulation of interleukin-8 expression by tumor-associated stress factors
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
    
    Q. Shi et al., "Regulation of interleukin-8 expression by tumor-associated stress factors", J INTERF CY, 21(8), 2001, pp. 553-566
22. Kramer, G; Steiner, GE; Sokol, P; Handisurya, A; Klingler, HC; Maier, U; Foldy, M; Marberger, M
    Local intratumoral tumor necrosis factor-alpha and systemic IFN-alpha 2b in patients with locally advanced prostate cancer
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
    
    G. Kramer et al., "Local intratumoral tumor necrosis factor-alpha and systemic IFN-alpha 2b in patients with locally advanced prostate cancer", J INTERF CY, 21(7), 2001, pp. 475-484
23. Xiong, QH; Shi, Q; Le, XD; Wang, BL; Xie, KP
    Regulation of interleukin-8 expression by nitric oxide in human pancreaticadenocarcinoma
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
    
    Q.H. Xiong et al., "Regulation of interleukin-8 expression by nitric oxide in human pancreaticadenocarcinoma", J INTERF CY, 21(7), 2001, pp. 529-537
24. Smith, ES; Mandokhot, A; Evans, EE; Mueller, L; Borrello, MA; Sahasrabudhe, DM; Zauderer, M
    Lethality-based selection of recombinant genes in mammalian cells: Application to identifying tumor antigens
    NATURE MEDICINE
    
    E.S. Smith et al., "Lethality-based selection of recombinant genes in mammalian cells: Application to identifying tumor antigens", NAT MED, 7(8), 2001, pp. 967-972
25. Masood, R; Cai, J; Tulpule, A; Zheng, T; Hamilton, A; Sharma, S; Espina, BM; Smith, DL; Gill, PS
    Interleukin 8 is an autocrine growth factor and a surrogate marker for Kaposi's sarcoma
    CLINICAL CANCER RESEARCH
    
    R. Masood et al., "Interleukin 8 is an autocrine growth factor and a surrogate marker for Kaposi's sarcoma", CLIN CANC R, 7(9), 2001, pp. 2693-2702
26. Bhoumik, A; Ivanov, V; Ronai, Z
    Activating transcription factor 2-derived peptides alter resistance of human tumor cell lines to ultraviolet irradiation and chemical treatment
    CLINICAL CANCER RESEARCH
    
    A. Bhoumik et al., "Activating transcription factor 2-derived peptides alter resistance of human tumor cell lines to ultraviolet irradiation and chemical treatment", CLIN CANC R, 7(2), 2001, pp. 331-342
27. Porter, GA; Abdalla, J; Lu, MS; Smith, S; Montgomery, D; Grimm, E; Ross, MI; Mansfield, PF; Gershenwald, JE; Lee, JE
    Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes
    ANNALS OF SURGICAL ONCOLOGY
    
    G.A. Porter et al., "Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes", ANN SURG O, 8(2), 2001, pp. 116-122
28. de Witte, H; van den Hurk, M; Sweep, F; Benraad, T; Geurts-Moespot, A; Ruiter, D; Verhofstad, A
    Development of quality control preparations for immunocytochemical assessment of urokinase-type plasminogen activator
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
    
    H. de Witte et al., "Development of quality control preparations for immunocytochemical assessment of urokinase-type plasminogen activator", APPL IMMUNO, 9(3), 2001, pp. 281-287
29. Toschi, E; Barillari, G; Sgadari, C; Bacigalupo, I; Cereseto, A; Carlei, D; Palladino, C; Zietz, C; Leone, P; Sturzl, M; Butto, S; Cafaro, A; Monini, P; Ensoli, B
    Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor
    MOLECULAR BIOLOGY OF THE CELL
    
    E. Toschi et al., "Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor", MOL BIOL CE, 12(10), 2001, pp. 2934-2946
30. Goodarzi, G; Mashimo, T; Watabe, M; Cuthbert, AP; Newbold, RF; Pai, SK; Hirota, S; Hosobe, S; Miura, K; Bandyopadhyay, S; Gross, SC; Balaji, KC; Watabe, K
    Identification of tumor metastasis suppressor region on the short arm of human chromosome 20
    GENES CHROMOSOMES & CANCER
    
    G. Goodarzi et al., "Identification of tumor metastasis suppressor region on the short arm of human chromosome 20", GENE CHROM, 32(1), 2001, pp. 33-42
31. Yang, YM; Hatch, WC; Liu, ZY; Du, B; Groopman, JE
    beta-chemokine induction of activation protein-1 and cyclic AMP responsiveelement activation in human myeloid cells
    CELL GROWTH & DIFFERENTIATION
    
    Y.M. Yang et al., "beta-chemokine induction of activation protein-1 and cyclic AMP responsiveelement activation in human myeloid cells", CELL GROWTH, 12(4), 2001, pp. 211-221
32. Yang, FC; Merlino, G; Chin, L
    Genetic dissection of melanoma pathways in the mouse
    SEMINARS IN CANCER BIOLOGY
    
    F.C. Yang et al., "Genetic dissection of melanoma pathways in the mouse", SEM CANC B, 11(3), 2001, pp. 261-268
33. Wittig, B; Marten, A; Dorbic, T; Weineck, S; Min, H; Niemitz, S; Trojaneck, B; Flieger, D; Kruopis, S; Albers, A; Loffel, J; Neubauer, A; Albers, P; Muller, S; Sauerbruch, T; Bieber, T; Huhn, D; Schmidt-Wolf, IGH
    Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: A first clinical phase I/II trial
    HUMAN GENE THERAPY
    
    B. Wittig et al., "Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: A first clinical phase I/II trial", HUM GENE TH, 12(3), 2001, pp. 267-278
34. Schraufstatter, IU; Chung, J; Burger, M
    IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways
    AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
    
    I.U. Schraufstatter et al., "IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways", AM J P-LUNG, 280(6), 2001, pp. L1094-L1103
35. Inoue, K; Wood, CG; Slaton, JW; Karashima, T; Sweeney, P; Dinney, CPN
    Adenoviral-mediated gene therapy of human bladder cancer with antisense interleukin-8
    ONCOLOGY REPORTS
    
    K. Inoue et al., "Adenoviral-mediated gene therapy of human bladder cancer with antisense interleukin-8", ONCOL REP, 8(5), 2001, pp. 955-964
36. Yutani, S; Shichijo, S; Inoue, Y; Kawagoe, N; Okuda, K; Kurohiji, T; Tanaka, M; Sata, M; Itoh, K
    Expression of the SART1 tumor-rejection antigen in hepatocellular carcinomas
    ONCOLOGY REPORTS
    
    S. Yutani et al., "Expression of the SART1 tumor-rejection antigen in hepatocellular carcinomas", ONCOL REP, 8(2), 2001, pp. 369-372
37. Izawa, JI; Slaton, JW; Kedar, D; Karashima, T; Perrotte, P; Czerniak, B; Grossman, HB; Dinney, CPN
    Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder
    ONCOLOGY REPORTS
    
    J.I. Izawa et al., "Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder", ONCOL REP, 8(1), 2001, pp. 9-15
38. Yu, YX; Heller, A; Liehr, T; Smith, CC; Aurelian, L
    Expression analysis and chromosome location of a novel gene (H11) associated with the growth of human melanoma cells
    INTERNATIONAL JOURNAL OF ONCOLOGY
    
    Y.X. Yu et al., "Expression analysis and chromosome location of a novel gene (H11) associated with the growth of human melanoma cells", INT J ONCOL, 18(5), 2001, pp. 905-911
39. Akiba, J; Yano, H; Ogasawara, S; Higaki, K; Kojiro, M
    Expression and function of interleukin-8 in human hepatocellular carcinoma
    INTERNATIONAL JOURNAL OF ONCOLOGY
    
    J. Akiba et al., "Expression and function of interleukin-8 in human hepatocellular carcinoma", INT J ONCOL, 18(2), 2001, pp. 257-264
40. Ahn, KS; Jung, YS; Kim, J; Lee, H; Yoon, SS
    Behavior of murine renal carcinoma cells crown in ectopic or orthotopic sites in syngeneic mice
    TUMOR BIOLOGY
    
    K.S. Ahn et al., "Behavior of murine renal carcinoma cells crown in ectopic or orthotopic sites in syngeneic mice", TUMOR BIOL, 22(3), 2001, pp. 146-153
41. Rich, BE; Kupper, TS
    Cytokines: IL-20 - a new effector in skin inflammation
    CURRENT BIOLOGY
    
    B.E. Rich e T.S. Kupper, "Cytokines: IL-20 - a new effector in skin inflammation", CURR BIOL, 11(13), 2001, pp. R531-R534
42. Jager, E; Jager, D; Knuth, A
    Vaccines in breast cancer
    BREAST
    
    E. Jager et al., "Vaccines in breast cancer", BREAST, 10, 2001, pp. 158-160
43. Kim, JY; Koo, HM; Kim, DSHL
    Development of C-20 modified betulinic acid derivatives as antitumor agents
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    
    J.Y. Kim et al., "Development of C-20 modified betulinic acid derivatives as antitumor agents", BIOORG MED, 11(17), 2001, pp. 2405-2408
44. Kageshita, T; Mizuno, M; Ono, T; Matsumoto, K; Saida, T; Yoshida, J
    Growth inhibition of human malignant melanoma transfected with the human interferon-beta gene by means of cationic liposomes
    MELANOMA RESEARCH
    
    T. Kageshita et al., "Growth inhibition of human malignant melanoma transfected with the human interferon-beta gene by means of cationic liposomes", MELANOMA RE, 11(4), 2001, pp. 337-342
45. Gunther, K; Fleischer, A; Buettner, R; Bosserhoff, AK
    Detection of invasion-related chromosomal changes in highly and weakly invasive melanoma cell clones by a modified comparative genomic hybridization approach
    MELANOMA RESEARCH
    
    K. Gunther et al., "Detection of invasion-related chromosomal changes in highly and weakly invasive melanoma cell clones by a modified comparative genomic hybridization approach", MELANOMA RE, 11(2), 2001, pp. 105-115
46. Vuoristo, MS; Laine, S; Huhtala, H; Parvinen, LM; Hahka-Kemppinen, M; Korpela, M; Kumpulainen, E; Kellokumpu-Lehtinen, P
    Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma
    EUROPEAN JOURNAL OF CANCER
    
    M.S. Vuoristo et al., "Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma", EUR J CANC, 37(13), 2001, pp. 1629-1634
47. Demeure, CE; Wolfers, J; Martin-Garcia, N; Gaulard, P; Triebel, F
    T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts
    EUROPEAN JOURNAL OF CANCER
    
    C.E. Demeure et al., "T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts", EUR J CANC, 37(13), 2001, pp. 1709-1718
48. Van den Eynde, BJ; Morel, S
    Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome
    CURRENT OPINION IN IMMUNOLOGY
    
    B.J. Van den Eynde e S. Morel, "Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome", CURR OP IM, 13(2), 2001, pp. 147-153
49. Wang, TT; Fan, LQ; Watanabe, Y; McNeill, P; Fanger, GR; Persing, DH; Reed, SG
    L552S, an alternatively spliced isoform of XAGE-1, is over-expressed in lung adenocarcinoma
    ONCOGENE
    
    T.T. Wang et al., "L552S, an alternatively spliced isoform of XAGE-1, is over-expressed in lung adenocarcinoma", ONCOGENE, 20(53), 2001, pp. 7699-7709
50. Knight, MJ; Riffkin, CD; Muscat, AM; Ashley, DM; Hawkins, CJ
    Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells
    ONCOGENE
    
    M.J. Knight et al., "Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells", ONCOGENE, 20(41), 2001, pp. 5789-5798
51. Maurici, D; Monti, P; Campomenosi, P; North, S; Frebourg, T; Fronza, G; Hainaut, P
    Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay
    ONCOGENE
    
    D. Maurici et al., "Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay", ONCOGENE, 20(27), 2001, pp. 3533-3540
52. Gershenwald, JE; Sumner, W; Calderone, T; Wang, Z; Huang, SY; Bar-Eli, M
    Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo
    ONCOGENE
    
    J.E. Gershenwald et al., "Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo", ONCOGENE, 20(26), 2001, pp. 3363-3375
53. Castro-Palomino, JC; Simon, B; Speer, O; Leist, M; Schmidt, RR
    Synthesis of ganglioside GD3 and its comparison with bovine GD3 with regard to oligodendrocyte apoptosis mitochondrial damage
    CHEMISTRY-A EUROPEAN JOURNAL
    
    J.C. Castro-Palomino et al., "Synthesis of ganglioside GD3 and its comparison with bovine GD3 with regard to oligodendrocyte apoptosis mitochondrial damage", CHEM-EUR J, 7(10), 2001, pp. 2178-2184
54. Gaumann, A; Petrow, P; Mentzel, T; Mayer, E; Dahm, M; Otto, M; Kirkpatrick, CJ; Kriegsmann, J
    Osteopontin expression in primary sarcomas of the pulmonary artery
    VIRCHOWS ARCHIV-AN INTERNATIONAL JOURNAL OF PATHOLOGY
    
    A. Gaumann et al., "Osteopontin expression in primary sarcomas of the pulmonary artery", VIRCHOWS AR, 439(5), 2001, pp. 668-674
55. Nagashima, H; Sadanaga, N; Mashino, K; Yamashita, K; Inoue, H; Mori, M; Sugimachi, K
    Expression of MAGE-B genes in esophageal squamous cell carcinoma
    JAPANESE JOURNAL OF CANCER RESEARCH
    
    H. Nagashima et al., "Expression of MAGE-B genes in esophageal squamous cell carcinoma", JPN J CANC, 92(2), 2001, pp. 167-173
56. Toda, M; Iizuka, Y; Yu, W; Imai, T; Ikeda, E; Yoshida, K; Kawase, T; Kawakami, Y; Okano, H; Uyemura, K
    Expression of the neural RNA-binding protein musashi1 in human gliomas
    GLIA
    
    M. Toda et al., "Expression of the neural RNA-binding protein musashi1 in human gliomas", GLIA, 34(1), 2001, pp. 1-7
57. Meyskens, FL; Farmer, P; Fruehauf, JP
    Redox regulation in human melanocytes and melanoma
    PIGMENT CELL RESEARCH
    
    F.L. Meyskens et al., "Redox regulation in human melanocytes and melanoma", PIGM CELL R, 14(3), 2001, pp. 148-154
58. Bar-Eli, M
    Gene regulation in melanoma progression by the AP-2 transcription factor
    PIGMENT CELL RESEARCH
    
    M. Bar-Eli, "Gene regulation in melanoma progression by the AP-2 transcription factor", PIGM CELL R, 14(2), 2001, pp. 78-85
59. Chambost, H; van Baren, N; Brasseur, F; Olive, D
    MAGE-A genes are not expressed in human leukemias
    LEUKEMIA
    
    H. Chambost et al., "MAGE-A genes are not expressed in human leukemias", LEUKEMIA, 15(11), 2001, pp. 1769-1771
60. Thomas, C; Yuki, N; Fertil, B
    Influence of gangliosides or LPS-like gangliosides on the tumoricidal activity of adherent leukocytes
    COMPTES RENDUS DE L ACADEMIE DES SCIENCES SERIE III-SCIENCES DE LA VIE-LIFE SCIENCES
    
    C. Thomas et al., "Influence of gangliosides or LPS-like gangliosides on the tumoricidal activity of adherent leukocytes", CR AC S III, 324(2), 2001, pp. 115-122
61. Zaffaroni, N; Fiorentini, G; De Giorgi, U
    Hyperthermia and hypoxia: new developments in anticancer chemotherapy
    EUROPEAN JOURNAL OF SURGICAL ONCOLOGY
    
    N. Zaffaroni et al., "Hyperthermia and hypoxia: new developments in anticancer chemotherapy", EUR J SUR O, 27(4), 2001, pp. 340-342
62. Tsuda, N; Murayama, K; Ishida, H; Matsunaga, K; Komiya, S; Itoh, K; Yamada, A
    Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytesby SART3-derived peptides
    JOURNAL OF ORTHOPAEDIC RESEARCH
    
    N. Tsuda et al., "Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytesby SART3-derived peptides", J ORTHOP R, 19(3), 2001, pp. 346-351
63. Dias, S; Choy, M; Rafii, S
    The role of CXC chemokines in the regulation of tumor angiogenesis
    CANCER INVESTIGATION
    
    S. Dias et al., "The role of CXC chemokines in the regulation of tumor angiogenesis", CANCER INV, 19(7), 2001, pp. 732-738
64. Kushner, BH; Kramer, K; Cheung, NKV
    Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma
    JOURNAL OF CLINICAL ONCOLOGY
    
    B.H. Kushner et al., "Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma", J CL ONCOL, 19(22), 2001, pp. 4189-4194
65. Baldi, A; Santini, D; Battista, T; Dragonetti, E; Ferranti, G; Petitti, T; Groeger, AM; Angelini, A; Rossiello, R; Baldi, F; Natali, PG; Paggi, MG
    Expression of AP-2 transcription factor and of its downstream target genesc-kit, E-cadherin and p21 in human cutaneous melanoma
    JOURNAL OF CELLULAR BIOCHEMISTRY
    
    A. Baldi et al., "Expression of AP-2 transcription factor and of its downstream target genesc-kit, E-cadherin and p21 in human cutaneous melanoma", J CELL BIOC, 83(3), 2001, pp. 364-372
66. Zambrano, A; Noli, C; Rauch, MC; Werner, E; Brito, M; Amthauer, R; Slebe, JC; Vera, JC; Concha, II
    Expression of GM-CSF receptors in male germ cells and their role in signaling for increased glucose and vitamin C transport
    JOURNAL OF CELLULAR BIOCHEMISTRY
    
    A. Zambrano et al., "Expression of GM-CSF receptors in male germ cells and their role in signaling for increased glucose and vitamin C transport", J CELL BIOC, 80(4), 2001, pp. 625-634
67. Chattopadhyay, N; Chatterjee, A
    Studies on the expression of alpha v beta 3 integrin receptors in non-malignant and malignant human cervical tumor tissues
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
    
    N. Chattopadhyay e A. Chatterjee, "Studies on the expression of alpha v beta 3 integrin receptors in non-malignant and malignant human cervical tumor tissues", J EXP CL C, 20(2), 2001, pp. 269-275
68. Ristic-Fira, A; Nikolic, D; Petrovic, I; Ruzdijic, S; Raffaele, L; Sabini, MG; Cirrone, GAP; Cuttone, G; Farruggia, G; Masotti, L; Kanazir, DT
    The late effects of proton irradiation on cell growth, cell cycle arrest and apoptosis in a human melanoma cell line
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
    
    A. Ristic-Fira et al., "The late effects of proton irradiation on cell growth, cell cycle arrest and apoptosis in a human melanoma cell line", J EXP CL C, 20(1), 2001, pp. 135-143
69. Lara, PN; Gandara, DR; Longmate, J; Gumerlock, PH; Martin, DHML; Edelman, J; Gandour-Edwards, R; Mack, PC; Israel, V; Raschko, J; Frankel, P; Perez, EA; Lenz, HJ; Doroshow, JH
    Activity of high-dose toremifene plus cisplatin in platinum-treated nonsmall-cell lung cancer: a phase II California Cancer Consortium Trial
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    P.N. Lara et al., "Activity of high-dose toremifene plus cisplatin in platinum-treated nonsmall-cell lung cancer: a phase II California Cancer Consortium Trial", CANC CHEMOT, 48(1), 2001, pp. 22-28
70. Thomas, C; Fertil, B
    Sensitivity of human melanoma cells to adherent leukocytes depends on the ratio between them, the activation status of adherent leukocytes and the metastatic potential of tumor cells
    CANCER IMMUNOLOGY IMMUNOTHERAPY
    
    C. Thomas e B. Fertil, "Sensitivity of human melanoma cells to adherent leukocytes depends on the ratio between them, the activation status of adherent leukocytes and the metastatic potential of tumor cells", CANCER IMMU, 50(4), 2001, pp. 181-190
71. Renkvist, N; Castelli, C; Robbins, PF; Parmiani, G
    A listing of human tumor antigens recognized by T cells
    CANCER IMMUNOLOGY IMMUNOTHERAPY
    
    N. Renkvist et al., "A listing of human tumor antigens recognized by T cells", CANCER IMMU, 50(1), 2001, pp. 3-15
72. Van Pel, A; De Plaen, E; Duffour, MT; Warnier, G; Uyttenhove, C; Perricaudet, M; Boon, T
    Induction of cytolytic T lymphocytes by immunization of mice with an adenovirus containing a mouse homolog of the human MAGE-A genes
    CANCER IMMUNOLOGY IMMUNOTHERAPY
    
    A. Van Pel et al., "Induction of cytolytic T lymphocytes by immunization of mice with an adenovirus containing a mouse homolog of the human MAGE-A genes", CANCER IMMU, 49(11), 2001, pp. 593-602
73. Thomas, C; Buronfosse, A; Courdi, A; Fertil, B
    Radio-prevention of micrometastases
    MEDICAL HYPOTHESES
    
    C. Thomas et al., "Radio-prevention of micrometastases", MED HYPOTH, 57(3), 2001, pp. 398-404
74. Lin, HC; Morin, PJ
    A novel homozygous deletion at chromosomal band 6q27 in an ovarian cancer cell line delineates the position of a putative tumor suppressor gene
    CANCER LETTERS
    
    H.C. Lin e P.J. Morin, "A novel homozygous deletion at chromosomal band 6q27 in an ovarian cancer cell line delineates the position of a putative tumor suppressor gene", CANCER LETT, 173(1), 2001, pp. 63-70
75. Nischt, R; Wallich, M; Reibetanz, M; Baumann, P; Krieg, T; Mauch, C
    BM-40 and MMP-2 expression are not coregulated in human melanoma cell lines
    CANCER LETTERS
    
    R. Nischt et al., "BM-40 and MMP-2 expression are not coregulated in human melanoma cell lines", CANCER LETT, 162(2), 2001, pp. 223-230
76. Varki, A
    N-glycolylneuraminic acid deficiency in humans
    BIOCHIMIE
    
    A. Varki, "N-glycolylneuraminic acid deficiency in humans", BIOCHIMIE, 83(7), 2001, pp. 615-622
77. Malykh, YN; Schauer, R; Shaw, L
    N-glycolylneuraminic acid in human tumours
    BIOCHIMIE
    
    Y.N. Malykh et al., "N-glycolylneuraminic acid in human tumours", BIOCHIMIE, 83(7), 2001, pp. 623-634
78. Woods, D; Cherwinski, H; Venetsanakos, E; Bhat, A; Gysin, S; Humbert, M; Bray, PF; Saylor, VL; McMahon, M
    Induction of beta 3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway
    MOLECULAR AND CELLULAR BIOLOGY
    
    D. Woods et al., "Induction of beta 3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway", MOL CELL B, 21(9), 2001, pp. 3192-3205
79. Bardeesy, N; Bastian, BC; Hezel, A; Pinkel, D; DePinho, RA; Chin, L
    Dual inactivation of RB and p53 pathways in RAS-induced melanomas
    MOLECULAR AND CELLULAR BIOLOGY
    
    N. Bardeesy et al., "Dual inactivation of RB and p53 pathways in RAS-induced melanomas", MOL CELL B, 21(6), 2001, pp. 2144-2153
80. Nyormoi, O; Wang, Z; Doan, D; Ruiz, M; McConkey, D; Bar-Eli, M
    Transcription factor AP-2 alpha is preferentially cleaved by caspase 6 anddegraded by proteasome during tumor necrosis factor alpha-induced apoptosis in breast cancer cells
    MOLECULAR AND CELLULAR BIOLOGY
    
    O. Nyormoi et al., "Transcription factor AP-2 alpha is preferentially cleaved by caspase 6 anddegraded by proteasome during tumor necrosis factor alpha-induced apoptosis in breast cancer cells", MOL CELL B, 21(15), 2001, pp. 4856-4867
81. Chen, WS; Yu, YL; Lee, SF; Chiang, YJ; Chao, JR; Huang, JH; Chiong, JH; Huang, CJ; Lai, MZ; Yang-Yen, HF; Yen, JJY
    CREB is one component of the binding complex of the Ces-2/E2A-HLF binding element and is an integral part of the interleukin-3 survival signal
    MOLECULAR AND CELLULAR BIOLOGY
    
    W.S. Chen et al., "CREB is one component of the binding complex of the Ces-2/E2A-HLF binding element and is an integral part of the interleukin-3 survival signal", MOL CELL B, 21(14), 2001, pp. 4636-4646
82. Wu, GJ; Varma, VA; Wu, MWH; Wang, SW; Qu, PP; Yang, HC; Petros, JA; Lim, SD; Amin, MB
    Expression of a human cell adhesion molecule, MUC18, in prostate cancer cell lines and tissues
    PROSTATE
    
    G.J. Wu et al., "Expression of a human cell adhesion molecule, MUC18, in prostate cancer cell lines and tissues", PROSTATE, 48(4), 2001, pp. 305-315
83. Kortylewski, M; Heinrich, PC; Kauffmann, ME; Bohm, M; Mackiewicz, A; Behrmann, I
    Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells
    BIOCHEMICAL JOURNAL
    
    M. Kortylewski et al., "Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells", BIOCHEM J, 357, 2001, pp. 297-303
84. Wang, YL; Devereux, W; Stewart, TM; Casero, RA
    Characterization of the interaction between the transcription factors human polyamine modulated factor (PMF-1) and NF-E2-related factor 2 (Nrf-2) in the transcriptional regulation of the spermidine/spermine N-1-acetyltransferase (SSAT) gene
    BIOCHEMICAL JOURNAL
    
    Y.L. Wang et al., "Characterization of the interaction between the transcription factors human polyamine modulated factor (PMF-1) and NF-E2-related factor 2 (Nrf-2) in the transcriptional regulation of the spermidine/spermine N-1-acetyltransferase (SSAT) gene", BIOCHEM J, 355, 2001, pp. 45-49
85. Olivares, C; Jimenez-Cervantes, C; Lozano, JA; Solano, F; Garcia-Borron, JC
    The 5,6-dihydroxyindole-2-carboxylic acid (DHICA) oxidase activity of human tyrosinase
    BIOCHEMICAL JOURNAL
    
    C. Olivares et al., "The 5,6-dihydroxyindole-2-carboxylic acid (DHICA) oxidase activity of human tyrosinase", BIOCHEM J, 354, 2001, pp. 131-139
86. Berd, D
    Autologous, hapten-modified vaccine as a treatment for human cancers
    VACCINE
    
    D. Berd, "Autologous, hapten-modified vaccine as a treatment for human cancers", VACCINE, 19(17-19), 2001, pp. 2565-2570
87. Vinals, C; Gaulis, S; Coche, T
    Using in silico transcriptomics to search for tumor-associated antigens for immunotherapy
    VACCINE
    
    C. Vinals et al., "Using in silico transcriptomics to search for tumor-associated antigens for immunotherapy", VACCINE, 19(17-19), 2001, pp. 2607-2614
88. Hiraki, A; Ono, T; Tanaka, M; Kiura, K; Ueoka, H; Kawai, H; Harada, M; Nakayama, E; Noguchi, Y
    Generation of cytotoxic T lymphocytes against autologous lung cancer cellsresistant to apoptosis
    ANTICANCER RESEARCH
    
    A. Hiraki et al., "Generation of cytotoxic T lymphocytes against autologous lung cancer cellsresistant to apoptosis", ANTICANC R, 21(4A), 2001, pp. 2561-2567
89. Hildebrandt, T; Van Dijk, MCRF; Van Muijen, GNP; Weidle, UH
    Loss of heterozygosity of gene THW is frequently found in melanoma metastases
    ANTICANCER RESEARCH
    
    T. Hildebrandt et al., "Loss of heterozygosity of gene THW is frequently found in melanoma metastases", ANTICANC R, 21(2A), 2001, pp. 1071-1080
90. Wataya, H; Kamikawaji, N; Nakanishi, Y; Takayama, K; Hara, N; Sasazuki, T
    Quantitation of HLA-A*0201 bound tumor associated antigens on a peptide pulsed B cell line
    HUMAN IMMUNOLOGY
    
    H. Wataya et al., "Quantitation of HLA-A*0201 bound tumor associated antigens on a peptide pulsed B cell line", HUMAN IMMUN, 62(2), 2001, pp. 125-132
91. Balazs, M; Adam, Z; Treszl, A; Begany, A; Hunyadi, J; Adany, R
    Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization
    CYTOMETRY
    
    M. Balazs et al., "Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization", CYTOMETRY, 46(4), 2001, pp. 222-232
92. Jain, RK
    Delivery of molecular and cellular medicine to solid tumors
    ADVANCED DRUG DELIVERY REVIEWS
    
    R.K. Jain, "Delivery of molecular and cellular medicine to solid tumors", ADV DRUG DE, 46(1-3), 2001, pp. 149-168
93. Jain, RK
    Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function
    JOURNAL OF CONTROLLED RELEASE
    
    R.K. Jain, "Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function", J CONTR REL, 74(1-3), 2001, pp. 7-25
94. Leszczyniecka, M; Roberts, T; Dent, P; Grant, S; Fisher, PB
    Differentiation therapy of human cancer: basic science and clinical applications
    PHARMACOLOGY & THERAPEUTICS
    
    M. Leszczyniecka et al., "Differentiation therapy of human cancer: basic science and clinical applications", PHARM THERA, 90(2-3), 2001, pp. 105-156
95. Dye, JF; Jablenska, R; Donnelly, JL; Lawrence, L; Leach, L; Clark, P; Firth, JA
    Phenotype of the endothelium in the human term placenta
    PLACENTA
    
    J.F. Dye et al., "Phenotype of the endothelium in the human term placenta", PLACENTA, 22(1), 2001, pp. 32-43
96. Nie, Y; Yang, GY; Song, YL; Zhao, X; So, C; Liao, J; Wang, LD; Yang, CS
    DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas
    CARCINOGENESIS
    
    Y. Nie et al., "DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas", CARCINOGENE, 22(10), 2001, pp. 1615-1623
97. Garrido, F; Algarra, I
    MHC antigens and tumor escape from immune surveillance
    ADVANCES IN CANCER RESEARCH, VOL 83
    
    F. Garrido e I. Algarra, "MHC antigens and tumor escape from immune surveillance", ADV CANC R, 83, 2001, pp. 117-158
98. Sakamoto, A; Oda, Y; Itakura, E; Oshiro, Y; Tamiya, S; Honda, Y; Ishihara, A; Iwamoto, Y; Tsuneyoshi, M
    H-, K-, and N-ras gene mutation in atypical fibroxanthoma and malignant fibrous histiocytoma
    HUMAN PATHOLOGY
    
    A. Sakamoto et al., "H-, K-, and N-ras gene mutation in atypical fibroxanthoma and malignant fibrous histiocytoma", HUMAN PATH, 32(11), 2001, pp. 1225-1231
99. Sakai, N; Baba, M; Nagasima, Y; Kato, Y; Hirai, K; Kondo, K; Kobayashi, K; Yoshida, M; Kaneko, S; Kishida, T; Kawakami, S; Hosaka, M; Inayama, Y; Yao, M
    SPARC expression in primary human renal cell carcinoma: Upregulation of SPARC in sarcomatoid renal carcinoma
    HUMAN PATHOLOGY
    
    N. Sakai et al., "SPARC expression in primary human renal cell carcinoma: Upregulation of SPARC in sarcomatoid renal carcinoma", HUMAN PATH, 32(10), 2001, pp. 1064-1070
100. Masson, C; Menaa, F; Pinon-Lataillade, G; Frobert, Y; Radicella, JP; Angulo, JF
     Identification of KIN (KIN17), a human gene encoding a nuclear DNA-bindingprotein, as a novel component of the TP53-independent response to ionizingradiation
     RADIATION RESEARCH
     
     C. Masson et al., "Identification of KIN (KIN17), a human gene encoding a nuclear DNA-bindingprotein, as a novel component of the TP53-independent response to ionizingradiation", RADIAT RES, 156(5), 2001, pp. 535-544